Objectives To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).

Objective To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK). Methods We performed a prospective cohort study in which baricitinib 4 ...

Objectives To determine whether antecedent sinusitis is associated with incident rheumatic disease. Methods This population-based case–control study included all individuals meeting classification ...

Objectives This study investigated: (1) the association of physical workload (PW) and risk of rheumatoid arthritis (RA); (2) the potential interactions between PW and the genes in the human leucocyte ...

Currently, traditional and non-traditional risk factors for cardiovascular disease have been established. The first group includes age, which constitutes one of the most important factors in the ...

Osteoarthritis (OA) of the knee is the most common arthritic disease, yet a convincing drug treatment is not available. The current narrative review focuses on integration of scientific evidence and ...

Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...

Objective The first biomarker associated with the rheumatoid arthritis is rheumatoid factor (RF) and since the earliest reports a role has been proposed in the diagnosis and in the prediction of ...

Within the health technology assessment framework, 1 an economic evaluation compares health technologies in terms of their costs, clinical effectiveness, side effects, impact on health-related quality ...

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...